Search Results

Engineered B Cell Medicine Gets Orphan Drug Status for Hemophilia

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. June 5, 2024

Record details

Beqvez Approved as One-Time Gene Therapy for Hemophilia

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. April 27, 2024

Record details

FDA approves Alhemo injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B with inhibitors.

• Source: PR Newswire. 2024.

Record details

FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B.

• Source: Plus Company Updates. 2024.

Record details

U.S. FDA Approves Pfizer's BEQVEZtm, a One-Time Gene Therapy for Adults with Hemophilia B.

• Source: Plus Company Updates. 2024.

Record details

Fidanacogene Elaparvovec, a Gene Therapy for Hemophilia B, Under Review

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. June 28, 2023

Record details

U.S. FDA APPROVES PFIZER'S BEQVEZA'cents (FIDANACOGENE ELAPARVOVEC-DZKT), A ONE-TIME GENE THERAPY FOR ADULTS WITH HEMOPHILIA B

• Source: States News Service. April 26, 2024

Record details

First Gene Therapy for Hemophilia B Gets FDA Approval

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. November 24, 2022

Record details

Rebinyn Approval for Hemophilia B Expanded to Include Routine Prophylaxis

• Authors : Park, Brian

• Source: MPR Monthly Prescribing Reference. August 3, 2022

Record details

Etranacogene Dezaparvovec, a Gene Therapy for Hemophilia B, Gets Priority Review

• Authors : Ernst, Diana

• Source: MPR Monthly Prescribing Reference. May 26, 2022

Record details